MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE
99.76
-1.16
-1.15%
Opening 13:37 12/05 EST
OPEN
99.42
PREV CLOSE
100.92
HIGH
99.88
LOW
98.91
VOLUME
1.80M
TURNOVER
0
52 WEEK HIGH
105.69
52 WEEK LOW
62.41
MARKET CAP
445.81B
P/E (TTM)
42.22
1D
5D
1M
3M
1Y
5Y
Law firms push to consolidate cases linked to weight loss drugs: Reuters
Law firms pushing to consolidate lawsuits over side effects of glp-1 class of weight loss drugs. Claimants have filed about 20 cases against novo nordisk and eli lilly since august. The lawsuits allege the companies played down or didn't warn consumers about side effects. Reuters: law firms want to consolidate the cases in a louisiana federal court.
Seeking Alpha · 1h ago
Eli Lilly’s (NYSE:LLY) Obesity Treatment Zepbound Enters the U.S. Obesity Market
TipRanks · 2h ago
Novo-Nordisk A/S: Report of foreign issuer
Press release · 4h ago
J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag
NASDAQ · 6h ago
The Fed Is Watching Jobs Data. Why It Should Be -2-
Take-two interactive software shares fell in early trading after a trailer for grand theft auto vi was released. The company said the video game franchise's next installment will be released in 2025. Take-two released the trailer after a leaked version of the game was leaked on social media.
Barron‘s · 7h ago
The Fed Is Watching Jobs Data. Why It Should Be Listening to Spotify.
Spotify says it is laying off 17% of its workforce. The streaming service is the latest company to announce job cuts this year. It's a big week for the labor market. Jobs data will be released every day through friday. Fed chairman jerome powell will likely be listening to the news.
Barron‘s · 7h ago
No more exercising? President RFK Jr.? Here’s one bank’s outrageous predictions for 2024
Denmark's saxo bank has a tradition of making "outrageous predictions" the bank predicts people will stop exercising as a result of the glp-1 obesity drugs. Robert f. Kennedy jr. Will be the winner of the 2024 election, the bank says. The bank also predicts that generative ai triggers a national security crisis.
MarketWatch · 8h ago
Mondelez: Still More Attractive Than Peers - I Am Buying
Mondelez international's shares are attractive compared to peers, with potential annual returns of approximately 13%. The company's exposure to faster-growing verticals, regional diversification, and strong management make it a compelling investment. Mondelez has been able to keep volumes positive despite price increases, demonstrating its strong product portfolio. I maintain my "buy" rating on mondelez international, inc. Following its strong q3 performance.
Seeking Alpha · 12h ago
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.